NASDAQ:RNXT RenovoRx (RNXT) Stock Price, News & Analysis $0.86 +0.02 (+1.76%) As of 12:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About RenovoRx Stock (NASDAQ:RNXT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RenovoRx alerts:Sign Up Key Stats Today's Range$0.84▼$0.8850-Day Range$0.79▼$1.1652-Week Range$0.70▼$1.45Volume78,110 shsAverage Volume327,329 shsMarket Capitalization$38.97 millionP/E RatioN/ADividend YieldN/APrice Target$8.25Consensus RatingModerate Buy Company Overview RenovoRx, Inc. is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers. RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors. By leveraging a patented catheter design, the system enables localized drug perfusion through arterial infusion, potentially enhancing tumor uptake of chemotherapeutic agents. RenovoRx has also entered strategic collaborations to advance its clinical programs, including licensing arrangements for development and commercialization in select international markets. Headquartered in Little Silver, New Jersey, RenovoRx conducts its clinical development activities through a network of investigative sites across the United States. The company’s management team comprises seasoned professionals with experience in interventional oncology, medical device development and regulatory affairs. As a Nasdaq-listed entity trading under the symbol RNXT, RenovoRx continues to advance its pipeline toward pivotal studies with the goal of offering new treatment options for patients with limited therapeutic alternatives.AI Generated. May Contain Errors. Read More RenovoRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreRNXT MarketRank™: RenovoRx scored higher than 55% of companies evaluated by MarketBeat, and ranked 469th out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingRenovoRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialRenovoRx has a consensus price target of $8.25, representing about 874.0% upside from its current price of $0.85.Amount of Analyst CoverageRenovoRx has only been the subject of 2 research reports in the past 90 days.Read more about RenovoRx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for RenovoRx are expected to grow in the coming year, from ($0.31) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RenovoRx is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RenovoRx is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRenovoRx has a P/B Ratio of 5.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about RenovoRx's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.24% of the float of RenovoRx has been sold short.Short Interest Ratio / Days to CoverRenovoRx has a short interest ratio ("days to cover") of 1.63, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RenovoRx has recently increased by 7.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRenovoRx does not currently pay a dividend.Dividend GrowthRenovoRx does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.29 News SentimentRenovoRx has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for RenovoRx this week, compared to 3 articles on an average week.Search Interest4 people have searched for RNXT on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows4 people have added RenovoRx to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, RenovoRx insiders have not sold or bought any company stock.Percentage Held by Insiders9.13% of the stock of RenovoRx is held by insiders.Percentage Held by Institutions3.10% of the stock of RenovoRx is held by institutions.Read more about RenovoRx's insider trading history. Receive RNXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNXT Stock News HeadlinesRenovoRx (RNXT) to Release Earnings on ThursdayMay 7, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA)May 1, 2026 | theglobeandmail.comThe system holding the dollar together is gone…Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every country on Earth to hold U.S. dollars to buy oil. Since then, Saudi Arabia has signed a $7 billion currency swap with China, begun settling oil in digital yuan, and joined China's cross-border payment system, mBridge. With 10-year Treasury yields pushing toward the 4.4% danger line and global dollar demand in retreat, gold is being repriced. There's one asset that still trades at a steep discount to gold's current price - a rare opportunity to leverage the metal's continued rise.May 12 at 1:00 AM | Golden Portfolio (Ad)RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ETApril 29, 2026 | globenewswire.comRenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual MeetingApril 23, 2026 | globenewswire.comRenovoRx (RNXT) price target decreased by 15.63% to 6.88April 16, 2026 | msn.comClinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific MeetingApril 14, 2026 | finance.yahoo.comClinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific MeetingApril 14, 2026 | globenewswire.comSee More Headlines RNXT Stock Analysis - Frequently Asked Questions How have RNXT shares performed this year? RenovoRx's stock was trading at $0.8401 at the beginning of 2026. Since then, RNXT stock has increased by 0.8% and is now trading at $0.8470. How were RenovoRx's earnings last quarter? RenovoRx, Inc. (NASDAQ:RNXT) released its earnings results on Monday, March, 30th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.42 million. RenovoRx had a negative net margin of 994.48% and a negative trailing twelve-month return on equity of 119.77%. Read the conference call transcript. When did RenovoRx IPO? RenovoRx (RNXT) raised $18 million in an initial public offering (IPO) on Thursday, August 26th 2021. The company issued 1,800,000 shares at $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO. Who are RenovoRx's major shareholders? Top institutional shareholders of RenovoRx include AIGH Capital Management LLC (8.23%). Insiders that own company stock include Ramtin Agah, Shaun Bagai, Laurence Marton, Ron Kocak and Angela Nelms. View institutional ownership trends. How do I buy shares of RenovoRx? Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of RenovoRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that RenovoRx investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), Bakkt (BKKT), NIO (NIO) and Phunware (PHUN). Company Calendar Last Earnings3/30/2026Today5/12/2026Next Earnings (Estimated)5/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (7m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 RNXT's financial health is in the Yellow zone, according to TradeSmith. RNXT has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNXT CIK1574094 Webwww.renovorx.com Phone650-284-4433Fax650-397-4433Employees6Year Founded2012Price Target and Rating Average Price Target for RenovoRx$8.25 High Price Target$13.50 Low Price Target$3.00 Potential Upside/Downside+853.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.17 million Net Margins-994.48% Pretax Margin-994.48% Return on Equity-119.77% Return on Assets-91.25% Debt Debt-to-Equity RatioN/A Current Ratio4.02 Quick Ratio3.93 Sales & Book Value Annual Sales$1.12 million Price / Sales34.79 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book5.77Miscellaneous Outstanding Shares45,050,000Free Float40,940,000Market Cap$38.97 million OptionableNot Optionable Beta1.00 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:RNXT) was last updated on 5/12/2026 by MarketBeat.com Staff. From Our PartnersBSEM: From OTC to Nasdaq Contender!BioStem Technologies (OTC: BSEM) has posted seven consecutive profitable quarters and just released audited fi...Huge Alerts | SponsoredYale just did the math (you owe Washington $1,500)The Yale Budget Lab calculated that current U.S. trade policy is costing the average American household betwee...Priority Gold | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredIs $24 trillion about to move?Bloomberg reports that S-P Dow Jones Indices is considering rule changes that could fast-track SpaceX into the...The Oxford Club | SponsoredSpaceX Launches Strange 'Dark Energy' Across AmericaSpaceX is deploying a newly permitted energy technology - one that analyst Joel Litman calls 'Dark Energy' - t...Altimetry | SponsoredRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
